2010). A total of 188 patients have been enrolled with 109 (58%) HLA-A2+/A3+ patients in the vaccine arm and 79 (42%) HLA-A2/A3- patients in the control arm. A 24-month landmark analysis revealed a recurrence rate of 6.5% in vaccinated patients compared to a recurrence rate of 14.5% in control patients (p=0.08). This benefit also appears to be durable with a persistent 35% relative risk reduction in breast cancer recurrences in vaccinated patients at 57 months of median follow-up. In subset analyses, patients found to derive the most benefit from vaccination included HER2 low or intermediate expressors (IHC 1+ or 2+), low grade tumors (grade 1 or 2), patients optimally dosed, and patients who underwent booster inoculations. The E75 vaccine will next be tested in a large, randomized multi-center Phase III industry-sponsored clinical trial. With the initial success of E75 in phase II trials and the successful extension of the vaccine population from HLA-A2+ patients only to include HLA-A3+ patients (described above), other preclinical work has been done with E75 and additional common HLA alleles. In fact, Sotiropoulou et al have confirmed CTL precursor frequencies from cancer patients responding to E75 in not only HLA-A2+ and HLA-A3+ patients, but also HLA-A26+ patients. Furthermore, their lab as well as ours has confirmed the algorithm predictions from both the SYFPEITHI & BIMAS systems that E75 binds to HLA-A24 as well. These data suggest that just as the E75 benefit was extended to HLA-A3+ patients, it may also extend to HLA-A24+ and 26+ patients. These two alleles are particularly prevalent in the Asian population.